Under AAAResearchReports.com Microscope: Star Scientific Inc., Pharmacyclics Inc., Impax Laboratories Inc., and United Therapeutics Corp. Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, October 30, 2013 LONDON, October 30, 2013 /PRNewswire/ -- The U.S. equity market posted gains on Tuesday, October 29, 2013, with the S&P 500, the Dow Jones Industrial Average, and the NASDAQ Composite rising 0.56%, 0.72%, and 0.31%, respectively. Shares in the healthcare-drug makers sector ended on a higher note, tracking gains in the broader market. The major movers in the sector included Star Scientific Inc. (NASDAQ: STSI), Pharmacyclics Inc. (NASDAQ: PCYC), Impax Laboratories Inc. (NASDAQ: IPXL), and United Therapeutics Corporation (NASDAQ: UTHR). AAAResearchReports.com has released full comprehensive research on STSI, PCYC, IPXL, and UTHR. These free technical analyses can be downloaded by signing up at: http://www.aaaresearchreports.com/register/ Star Scientific Inc.'s stock gained 2.14% on Tuesday, ending the day at an intra-day high of $1.91, after fluctuating between $1.86 and $1.91 during the trading session. A total of 0.41 million shares were traded, which is below the daily average volume of 0.86 million. The company's shares have gained 2.69% in the previous three months, compared to a gain of 5.14% in the S&P 500 during the same period. Additionally, Star Scientific Inc.'s stock is trading above its 200-day moving average of $1.77. A free technical analysis on STSI available by signing up at: http://www.AAAResearchReports.com/STSI103013.pdf On Tuesday, Pharmacyclics Inc.'s shares posted gains, ending the day at intra-day high of $125.09, which is 0.66% higher than the previous day's closing price of $124.27. The company's shares fluctuated between $122.19 and $125.09 during the trading session. A total of 0.53 million shares were traded, which is below the daily average volume of 0.72 million. Pharmacyclics Inc.'s shares have surged 19.80% in the previous three months, outperforming the S&P 500, which has gained 5.14% during the same period. Moreover, the company's stock is trading above its 50-day and 200-day moving averages of $123.11 and $95.36, respectively. Register today and access free research on PCYC at: http://www.AAAResearchReports.com/PCYC103013.pdf Impax Laboratories Inc.'s shares ended the day 0.34% higher at $20.68, after oscillating between $20.33 and $20.74 during Tuesday's trading session. A total of 0.26 million shares were traded, which is below the daily average volume of 0.42 million. Impax Laboratories Inc.'s stock has gained 1.82% in the previous one month, underperforming the S&P 500, which has gained 4.74% during the same period. Further, the company's shares are trading above their 50-day and 200-day moving averages of $20.50 and $19.17, respectively. The free report on IPXL can be downloaded by signing up now at: http://www.AAAResearchReports.com/IPXL103013.pdf United Therapeutics Corp.'s stock surged 3.73% on Tuesday, hitting a new 52-week high of $87.50. The company's shares finished the day at $86.50 after vacillating between $83.65 and $87.50 during the trading session. A total of 1.05 million shares were traded, which is significantly above the daily average volume of 0.45 million. The company's stock has gained 9.88% in the previous one month and 19.10% in the previous three months, compared to a gain of 4.74% and 5.14% in the S&P 500 during the respective periods. Furthermore, United Therapeutics Corp.'s stock is trading above its 50-day and 200-day moving averages of $78.24 and $67.13, respectively. A free report on UTHR can be accessed by registering at: http://www.AAAResearchReports.com/UTHR103013.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AAAresearchreports.com SOURCE AAA Research Reports Contact: +1(646)396-9126, Peter F. Jones, firstname.lastname@example.org
Under AAAResearchReports.com Microscope: Star Scientific Inc., Pharmacyclics Inc., Impax Laboratories Inc., and United
Press spacebar to pause and continue. Press esc to stop.